Latest ABK Biomedical News & Updates

See the latest news and media coverage for ABK Biomedical. We track all announcements, press releases, and industry mentions in real time, all in one place.

ABK Biomedical

Developer of radioembolization treatments for liver tumors

abkbiomedical.com

Headquarters: Halifax, Canada
Founded year: 2012
Company type: Private company
Number of employees: 40–50

Last updated Today

Latest news about ABK Biomedical

In short: ABK Biomedical raised $35 million in Series D funding and launched a commercial manufacturing facility to support its Eye90 cancer therapy.

Company announcements

April 9 ABK Biomedical

ABK Biomedical presents clinical data comparing dosimetry modalities

At SIR2026, new data on Eye90 microspheres compares NM and CT-based dosimetry after Y90 radioembolization.

April 8 ABK Biomedical

ABK Biomedical announces manufacturing facility in Ashland

The company and COR Development will build a GMP facility to produce Eye90 microspheres for commercial Y-90 radioembolization, near MURR, enabling scaled supply.

February 24 ABK Biomedical

ABK Biomedical completed enrollment in pivotal ROUTE90 study

The study is the largest prospective FDA IDE trial for Y90 treatment of hepatocellular carcinoma, enrolling 120 patients.

5 December 2023 ABK Biomedical

ABK Biomedical's Eye90 microspheres granted FDA Breakthrough Device Designation

The designation is for treating unresectable hepatocellular carcinoma and will expedite FDA interactions.

Media coverage

March 31 Yahoo Finance

ABK Biomedical and MURR Forge Long-Term Partnership to Advance Breakthrough Cancer Therapy

HALIFAX, NS, March 31, 2026 /CNW/ - ABK Biomedical and the University of Missouri Research Reactor (MURR) are powering the next generation of cancer treatment...

15 October 2025 Goodman's

ABK Biomedical Secures US$35 Million Series D Financing to Advance Liver Cancer Treatment | Goodmans LLP

Halifax-based medical device company ABK Biomedical, Inc. (“ABK Biomedical”) has raised US$35M in Series D financing to support the commercialization of...

5 December 2023 Western Radio Group

ABK Biomedical announces that its Eye90 microspheres® device has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA)

HALIFAX, NS, Dec. 5, 2023 /PRNewswire/ - ABK Biomedical, Inc., an innovative, medical device company dedicated to the research, development, and commercialization of advanced imageable...

12 September 2022 FOX31 Denver

ABK Biomedical announces FDA 510(k) clearance of Easi-Vue™ embolic microspheres for the embolization of arteriovenous malformations and hypervascular tumors

HALIFAX, NS, Sept. 12, 2022 /PRNewswire/ - ABK Biomedical, Inc., an innovative medical device company dedicated to the research, development, and commercialization of advanced imageable...

Never miss news about ABK Biomedical

Track ABK Biomedical and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.